These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31808867)

  • 1. Relapsed disease and aspects of undetectable MRD and treatment discontinuation.
    Eichhorst B; Fürstenau M; Hallek M
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):482-489. PubMed ID: 31808867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
    Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ
    J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
    Kater AP; Wu JQ; Kipps T; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Dubois J; Eldering E; Mellink C; Van Der Kevie-Kersemaekers AM; Kim SY; Chyla B; Punnoose E; Bolen CR; Assaf ZJ; Jiang Y; Wang J; Lefebure M; Boyer M; Humphrey K; Seymour JF
    J Clin Oncol; 2020 Dec; 38(34):4042-4054. PubMed ID: 32986498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
    Seymour JF; Kipps TJ; Eichhorst BF; D'Rozario J; Owen CJ; Assouline S; Lamanna N; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Mellink C; Chyla B; Panchal A; Lu T; Wu JQ; Jiang Y; Lefebure M; Boyer M; Kater AP
    Blood; 2022 Aug; 140(8):839-850. PubMed ID: 35605176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.
    Ma S; Seymour JF; Brander DM; Kipps TJ; Choi MY; Anderson MA; Humphrey K; Al Masud A; Pesko J; Nandam R; Salem AH; Chyla B; Arzt J; Jacobson A; Kim SY; Roberts AW
    Blood; 2021 Sep; 138(10):836-846. PubMed ID: 34115103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies).
    ESMO Guidelines Committee
    Ann Oncol; 2017 Jul; 28(suppl_4):iv149-iv152. PubMed ID: 28881925
    [No Abstract]   [Full Text] [Related]  

  • 8. Venetoclax plus rituximab for chronic lymphocytic leukaemia.
    Stirrups R
    Lancet Oncol; 2018 May; 19(5):e233. PubMed ID: 29606585
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
    Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
    Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
    N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Rogers KA; Huang Y; Ruppert AS; Abruzzo LV; Andersen BL; Awan FT; Bhat SA; Dean A; Lucas M; Banks C; Grantier C; Heerema NA; Lozanski G; Maddocks KJ; Valentine TR; Weiss DM; Jones JA; Woyach JA; Byrd JC
    J Clin Oncol; 2020 Nov; 38(31):3626-3637. PubMed ID: 32795224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
    Fürstenau M; Langerbeins P; De Silva N; Fink AM; Robrecht S; von Tresckow J; Simon F; Hohloch K; Droogendijk J; van der Klift M; van der Spek E; Illmer T; Schöttker B; Fischer K; Wendtner CM; Tausch E; Stilgenbauer S; Niemann CU; Gregor M; Kater AP; Hallek M; Eichhorst B
    Leukemia; 2020 Aug; 34(8):2225-2229. PubMed ID: 32601378
    [No Abstract]   [Full Text] [Related]  

  • 13. MRD to help assess response in CLL.
    Romero D
    Nat Rev Clin Oncol; 2019 Feb; 16(2):68. PubMed ID: 30573789
    [No Abstract]   [Full Text] [Related]  

  • 14. CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLL.
    Fakhri B; Andreadis C
    Oncology (Williston Park); 2019 Nov; 33(11):. PubMed ID: 31769861
    [No Abstract]   [Full Text] [Related]  

  • 15. Autoimmune hemolytic anemia, adverse event to venetoclax.
    Carriles C; Ordóñez-Fernández L; Arias-Martínez A; Menárguez-Blanc R; Rosado-María MC
    Farm Hosp; 2019 Sep; 43(5):166-167. PubMed ID: 31469630
    [No Abstract]   [Full Text] [Related]  

  • 16. Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
    Thompson M; Brander D; Nabhan C; Mato A
    JAMA Oncol; 2018 Mar; 4(3):394-400. PubMed ID: 28750119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia.
    Molica S; Allsup D; Gianfelici V; Levato L; Aiello V; Bailey J; Polliack A
    Expert Opin Investig Drugs; 2021 Jun; 30(6):621-633. PubMed ID: 33929928
    [No Abstract]   [Full Text] [Related]  

  • 18. Venetoclax Data Prompt Rethink of CLL Therapy.
    Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months.
    Lew TE; Anderson MA; Lin VS; Handunnetti SM; Came NA; Blombery P; Westerman DA; Wall M; Tam CS; Roberts AW; Seymour JF
    Blood Adv; 2020 Jan; 4(1):165-173. PubMed ID: 31935286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
    Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
    Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.